Retour

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

News Press releases

Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston

GlobeNewswire Inc. • 08/05/2024 à 15:25:00
Lixte Biotechnology Holdings, Inc. Common Stock
Address: 248 ROUTE 25A
Postal Code: 11733
City: EAST SETAUKET
State: NY
Phone Number: 310 203 2902
Website: https://www.lixte.com
Status: Active
Company Info

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

List Date2007-09-05
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001335105
Composite figiBBG000TC15T7
Share Class figiBBG001SZV9C2
Market Cap5,534,153 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees4
Share Class Shares Outstanding2250000
Weighted Shares Outstanding2249290
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
2.275
2.4
2.62
2.64
2.665
Variance
-6.3%
-8.29%
-0.76%
-0.94%
4.92%
Open
2.428
2.617
2.64
2.665
2.54
Highest
2.639
2.617
2.775
2.849
2.785
Lowest
2.611
2.601
2.72
2.838
2.785
History
PeriodVarhighestlowest
1 week
-10.43%
2.785
2.601
1 month
-33.13%
3.589
2.601
3 month
-32.33%
3.362
2.256
6 month
-23.5%
3.22
1.69
1 year
-62.08%
6.63
1.58
3 year
-92.54%
30.733
1.58
5 year
-94.31%
41.25
1.58
10 year
-94.31%
41.25
1.58
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-09 UNPUB
Assets 4,330,816 3,095,148 5,234,696 UNPUB
Current Assets 4,330,816 3,095,148 5,234,696 UNPUB
Current Liabilities 249,987 402,614 311,736 UNPUB
Equity 4,080,829 2,692,534 4,922,960 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 4,080,829 2,692,534 4,922,960 UNPUB
Liabilities 249,987 402,614 311,736 UNPUB
Liabilities And Equity 4,330,816 3,095,148 5,234,696 UNPUB
Noncurrent Assets 0 0 0 UNPUB
Noncurrent Liabilities 0 0 0 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-09 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 UNPUB
Net Cash Flow, Continuing 0 0 0 UNPUB
Net Cash Flow From Financing Activities 6,281 0 3,137,080 UNPUB
Net Cash Flow From Financing Activities, Continuing 6,281 0 3,137,080 UNPUB
Net Cash Flow From Investing Activities 1,265,088 1,175,384 -2,192,691 UNPUB
Net Cash Flow From Investing Activities, Continuing 1,265,088 1,175,384 -2,192,691 UNPUB
Net Cash Flow From Operating Activities -1,271,369 -1,175,384 -944,389 UNPUB
Net Cash Flow From Operating Activities, Continuing -1,271,369 -1,175,384 -944,389 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-09 UNPUB
Comprehensive Income/Loss -1,367,659 -1,668,355 -1,018,760 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -1,367,659 -1,668,355 -1,018,760 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-09 2023-11-09 UNPUB
Basic Earnings Per Share 0 -1 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue 519,480 522,561 356,001 UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB -1 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -1,367,659 -1,668,355 -1,018,760 UNPUB
Income/Loss From Continuing Operations Before Tax -1,367,659 -1,668,355 -1,018,760 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 3,861 1,948 279 UNPUB
Net Income/Loss -1,367,659 -1,668,355 -1,018,760 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -1,367,659 -1,668,355 -1,018,760 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -1,367,659 -1,668,355 -1,018,760 UNPUB
Operating Expenses 1,370,147 1,669,998 1,024,181 UNPUB
Operating Income/Loss -1,370,147 -1,669,998 -1,024,181 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-08 2023-03-29
Assets 4,117,685 8,023,806 6,819,468 5,560,013
Current Assets 4,106,779 8,023,806 6,819,468 5,560,013
Current Liabilities 644,593 531,540 408,328 394,786
Equity 3,473,092 7,492,266 6,411,140 5,165,227
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 3,473,092 7,492,266 6,411,140 5,165,227
Liabilities -3,473,092 -7,492,266 408,328 394,786
Liabilities And Equity 4,117,685 8,023,806 6,819,468 5,560,013
Noncurrent Assets 10,906 0 0 0
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-08 2023-03-29
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities -10,906 5,152,290 0 5,141,384
Net Cash Flow From Financing Activities, Continuing -10,906 5,152,290 0 5,141,384
Net Cash Flow From Investing Activities 1,046,003 -3,958,030 1,173,932 -529,647
Net Cash Flow From Investing Activities, Continuing 1,046,003 -3,958,030 1,173,932 -529,647
Net Cash Flow From Operating Activities -1,035,097 -1,194,260 -1,173,932 -4,611,737
Net Cash Flow From Operating Activities, Continuing -1,035,097 -1,194,260 -1,173,932 -4,611,737
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-08 2023-03-29
Comprehensive Income/Loss -1,656,918 -1,546,304 -1,478,009 -6,312,535
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -1,656,918 -1,546,304 -1,478,009 -6,312,535
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-08 2023-03-29
Basic Earnings Per Share 0 0 0 0
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -1,656,918 -1,546,304 -1,478,009 -6,312,535
Income/Loss From Continuing Operations Before Tax -1,656,918 -1,546,304 -1,478,009 -6,312,535
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 2,494 627 UNPUB 8,875
Net Income/Loss -1,656,918 -1,546,304 -1,478,009 -6,312,535
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -1,656,918 -1,546,304 -1,478,009 -6,312,535
Net Income/Loss Available To Common Stockholders, Basic -1,656,918 -1,546,304 -1,478,009 -6,312,535
Operating Expenses 1,654,352 1,546,010 1,478,501 6,311,481
Operating Income/Loss -1,654,352 -1,546,010 -1,478,501 -6,311,481
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-10 2021-11-10 2022-03-21
Assets 7,890,100 7,242,664 6,333,535 5,093,264
Current Assets 7,890,100 7,242,664 6,307,159 5,093,264
Current Liabilities 242,400 376,326 258,699 302,926
Equity 7,647,700 6,866,338 6,074,836 4,790,338
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 7,647,700 6,866,338 6,074,836 4,790,338
Liabilities -7,647,700 -6,866,338 258,699 302,926
Liabilities And Equity 7,890,100 7,242,664 6,333,535 5,093,264
Noncurrent Assets 0 0 26,376 0
Noncurrent Liabilities 0 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-10 2021-11-10 2022-03-21
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 0
Net Cash Flow, Continuing 0 0 0 0
Net Cash Flow From Financing Activities 3,696,394 101,000 90,000 3,897,394
Net Cash Flow From Financing Activities, Continuing 3,696,394 101,000 90,000 3,897,394
Net Cash Flow From Investing Activities -2,670,057 940,846 837,883 245,521
Net Cash Flow From Investing Activities, Continuing -2,670,057 940,846 837,883 245,521
Net Cash Flow From Operating Activities -1,026,337 -1,041,846 -927,883 -4,142,915
Net Cash Flow From Operating Activities, Continuing -1,026,337 -1,041,846 -927,883 -4,142,915
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-10 2021-11-10 2022-03-21
Comprehensive Income/Loss -1,727,144 -1,733,166 -1,238,724 -6,728,396
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -1,727,144 -1,733,166 -1,238,724 -6,728,396
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-10 2021-11-10 2022-03-21
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -1,727,144 -1,733,166 -1,238,724 -6,728,396
Income/Loss From Continuing Operations Before Tax -1,727,144 -1,733,166 -1,238,724 -6,728,396
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 2,110 UNPUB UNPUB 7,414
Net Income/Loss -1,727,144 -1,733,166 -1,238,724 -6,728,396
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -1,727,144 -1,733,166 -1,238,724 -6,728,396
Net Income/Loss Available To Common Stockholders, Basic -1,727,144 -1,733,166 -1,238,724 -6,728,396
Operating Expenses 1,725,180 1,732,595 1,237,720 6,720,445
Operating Income/Loss -1,725,180 -1,732,595 -1,237,720 -6,720,445
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-26
Assets UNPUB UNPUB UNPUB 5,228,475
Current Assets UNPUB UNPUB UNPUB 5,228,475
Current Liabilities UNPUB UNPUB UNPUB 216,524
Equity UNPUB UNPUB UNPUB 5,011,951
Equity Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Equity Attributable To Parent UNPUB UNPUB UNPUB 5,011,951
Liabilities UNPUB UNPUB UNPUB 216,524
Liabilities And Equity UNPUB UNPUB UNPUB 5,228,475
Noncurrent Assets UNPUB UNPUB UNPUB 0
Noncurrent Liabilities UNPUB UNPUB UNPUB 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-26
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB UNPUB 0
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 0
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 4,601,816
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 4,601,816
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB -6,733,230
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB -6,733,230
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB 2,131,414
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB 2,131,414
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-26
Comprehensive Income/Loss UNPUB UNPUB UNPUB -3,264,882
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -3,264,882
Other Comprehensive Income/Loss UNPUB UNPUB UNPUB 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-26
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB UNPUB -3,264,882
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB UNPUB -3,264,882
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB 3,674
Net Income/Loss UNPUB UNPUB UNPUB -3,264,882
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Net Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -3,264,882
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB UNPUB -3,264,882
Operating Expenses UNPUB UNPUB UNPUB 3,266,440
Operating Income/Loss UNPUB UNPUB UNPUB -3,266,440
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB UNPUB 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB UNPUB 0
Revenues UNPUB UNPUB UNPUB 0
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
News Stream
News Press releases
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston
GlobeNewswire Inc. • 1w ago
stocks News
Crude Oil Edges Lower; PaySign Shares Spike Higher
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 200 points on Wednesday. The Dow traded up 0.56% to 39,502.25 while the NASDAQ fell 0.08% to 16,302.03. The S&P 500 also rose, gaining, 0.27% to 5,217.52. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1   Leading and Lagging Sectors   Real estate shares jumped by 1.8% on Wednesday. In trading on Wednesday, information technology shares fell by 0.4%.   Top Headline   Crude oil inventories in the U.S. increased by 3.165 million barrels in the week ended March 22, compared to market estimates of a 1.275 million decline, the Energy Information Administration said.   Equities Trading UP   Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares shot up 49% to $3.38 after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100. Shares of MariaDB plc (NYSE: MRDB) got a boost, surging 73% to $0.39 after Progress Software announced that it is possibly considering an offer for the company. PaySign, Inc. ...
Benzinga • 1mo ago
News News
Crude Oil Edges Lower; PaySign Shares Spike Higher
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 200 points on Wednesday. The Dow traded up 0.56% to 39,502.25 while the NASDAQ fell 0.08% to 16,302.03. The S&P 500 also rose, gaining, 0.27% to 5,217.52. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1   Leading and Lagging Sectors   Real estate shares jumped by 1.8% on Wednesday. In trading on Wednesday, information technology shares fell by 0.4%.   Top Headline   Crude oil inventories in the U.S. increased by 3.165 million barrels in the week ended March 22, compared to market estimates of a 1.275 million decline, the Energy Information Administration said.   Equities Trading UP   Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares shot up 49% to $3.38 after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100. Shares of MariaDB plc (NYSE: MRDB) got a boost, surging 73% to $0.39 after Progress Software announced that it is possibly considering an offer for the company. PaySign, Inc. ...
Benzinga • 1mo ago
News Press releases
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.
GlobeNewswire Inc. • 1mo ago
News Press releases
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies
GlobeNewswire Inc. • 2mo ago
News Press releases
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).
GlobeNewswire Inc. • 3mo ago
News Press releases
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D.
GlobeNewswire Inc. • 7mo ago
News Press releases
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman
GlobeNewswire Inc. • 7mo ago
News Press releases
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A
GlobeNewswire Inc. • 8mo ago
News Press releases
LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the closing of its previously announced registered direct offering of 583,334 shares of common stock (or common stock equivalents in lieu thereof) and concurrent private placement of common warrants to purchase up to 583,334 shares of common stock (together with the registered direct offering, the “Offering”) at a purchase price of $6.00 per common share, priced “at-the-market” under Nasdaq rules. The common warrants issued pursuant to the concurrent private placement have an exercise price of $6.00 per share, are exercisable immediately upon issuance and will expire 5 years from issuance.
GlobeNewswire Inc. • 10mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT